logo
Share SHARE
FONT-SIZE Plus   Neg

Summit Signs Technology License Deal With Bristol-Myers Squibb

UK-based drug company Summit Corp plc. (SUMM.L) Tuesday said it entered into a technology-license agreement with Bristol-Myers Squibb. Summit's Seglin technology, which develops drug candidates for up to ten targets across multiple therapeutic areas, is of interest to Squibb, which will pay a $100 thousand technology access fee plus regulatory milestones of up to $30 million per product synthesized to Summit.

Bristol-Myers Squibb shall take responsiblity for the discovery stage of the research and have exclusive rights to develop and commercialize all Seglin products identified, said Summit in a statement.

The stock is currently trading at 2.50 pence, up 0.13 pence or 5.26 percent on the LSE.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
After falling sharply in early trading, stocks showed a substantial turnaround over the course of the trading session on Tuesday. The major averages bounced well off their lows for the session and into positive territory. Coca-Cola announced that it is removing its trademark logo from cans in the Middle East as part of the soda giant's marketing campaign to fight prejudice. The company has replaced its famous trademark logo with "Labels are for cans not people," message. The company has made the change during the... Carnival said it has obtained U.S. approval to begin cruises to Cuba. The announcement by the cruise operator follows the recent restoration of diplomatic relations between the U.S. and Cuba.
comments powered by Disqus
Follow RTT